OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Chien on Tucatinib in HER2+ Breast Cancer

March 12th 2019

A. Jo Chien, MD, associate clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the use of tucatinib (ONT-380) in the treatment of patients with HER2-positive breast cancer.

Dr. Naidoo on Considerations for Managing irAEs in NSCLC

March 11th 2019

Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses considerations for managing immune-related adverse events in patients with non–small cell lung cancer.

Dr. Patel Discusses Zanubrutinib in MCL

March 11th 2019

Krish Patel, MD, medical oncologist, Swedish Cancer Institute, discusses zanubrutinib in the treatment of patients with mantle cell lymphoma.

Dr. Powles on Rationale for KEYNOTE-426 in mRCC

March 11th 2019

Thomas Powles, MBBS, MRCP, MD, director, Barts Cancer Institute, discusses the rationale for the KEYNOTE-426 study in patients with metastatic renal cell carcinoma.

Dr. Davids Discusses Frontline Approaches in CLL

March 9th 2019

Matthew S. Davids, MD, MMSc, associate director, CLL Center, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discusses frontline treatment approaches for patients with chronic lymphocytic leukemia.

Dr. Holstein on Recent Data With Venetoclax in Myeloma

March 9th 2019

Sarah Holstein, MD, PhD, associate professor of medicine, University of Nebraska Medical Center, discusses recent data with venetoclax in the treatment of patients with myeloma.

Dr. Padda on Novel Combinations for EGFR+ NSCLC

March 9th 2019

Sukhmani Padda, MD, assistant professor of medicine, Stanford University Medical Center, member, Stanford Cancer Institute, discusses novel combinations in the treatment of patients with EGFR-positive non–small cell lung cancer.

Dr. Jiang on the Future of Immunotherapy in Microsatellite Stable Colorectal Cancer

March 9th 2019

Yixing Jiang, BM, PhD, associate professor of medicine, director, Gastrointestinal Medical Oncology Marlene Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, discusses the future of immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC).

Dr. O'Sullivan on Individualized HER2-Targeted Therapy in HER2+ Breast Cancer

March 9th 2019

Ciara O'Sullivan, MB, BCh, senior associate consultant, assistant professor of oncology, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses how HER2-targeted treatment can be more individualized in the treatment of patients with HER2-positive breast cancer.

Dr. Grivas on Bladder Preservation in Localized Bladder Cancer

March 9th 2019

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, oncology, University of Washington, Seattle Cancer Care Alliance, discusses data on bladder preservation in patients with localized bladder cancer.

Dr. Hamilton on FDA Approval of Atezolizumab/Nab-Paclitaxel in TNBC

March 8th 2019

Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses the FDA approval of atezolizumab and nab-paclitaxel as a frontline therapy for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer.

Dr. Kambhampati on the Potential of CAR T-Cell Therapy in CLL

March 8th 2019

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in chronic lymphocytic leukemia (CLL).

Dr. Mettu on the Potential of CPI-613 in Metastatic Pancreatic Cancer

March 8th 2019

Niharika B. Mettu, MD, PhD, assistant professor medicine, Duke Cancer Institute, discusses the potential of CPI-613 in the treatment of patients with metastatic pancreatic cancer.

Dr. Seymour on Promising Combinations in CLL

March 8th 2019

Erlene Seymour, MD, assistant professor of medicine, Karmanos Cancer Institute, Wayne State University, discusses promising combination therapies in the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Konstantinopoulos on Immunotherapy in Ovarian Cancer

March 8th 2019

Panagiotis A. Konstantinopoulos, MD, PhD, director of Translational Research, Gynecologic Oncology, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the role of immunotherapy in the treatment of patients with ovarian cancer.

Dr. Meric-Bernstam on CB-839 Plus Cabozantinib in RCC

March 8th 2019

Funda Meric-Bernstam, MD, chair, Department of Investigational Cancer Therapeutics, medical director, Institute for Personalized Cancer Therapy, professor of medicine, The University of Texas MD Anderson Cancer Center, discusses the combination of CB-839 plus cabozantinib in patients with renal cell carcinoma.

Dr. Pal on Molecular Signatures in Renal Cell Carcinoma

March 7th 2019

Sumanta Kumar Pal, MD, a medical oncologist at City of Hope, discusses the emergence of molecular signatures in patients with renal cell carcinoma (RCC).

Dr. Dorff on PARP Inhibitors in Prostate Cancer

March 7th 2019

Tanya B. Dorff, MD, associate clinical professor in the Department of Medical Oncology and Therapeutics Research, and head of the genitourinary cancers program at City of Hope, discusses the use of PARP inhibitors in prostate cancer.

Dr. Sabari Discusses the Utility of Liquid Biopsies in Lung Cancer

March 7th 2019

Joshua K. Sabari, MD, assistant professor, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, discusses the utility of liquid biopsies in lung cancer.

Dr. Lonial on Treatment of Patients With Late Relapse Myeloma

March 7th 2019

Sagar Lonial, MD, professor and chair, Department of Hematology and Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the treatment of patients with late relapse myeloma.